An international panel of experts from The Heart Rhythm Society and the European Heart Rhythm Association issued new guideline recommendations for all health care professionals about cardiovascular genetic testing at the Heart Rhythm Society's 32nd Annual Scientific Sessions.
Silvia G. Priori, MD, PhD, a leader in the field of inherited cardiovascular diseases and director of the Cardiovascular Genetics Program at NYU Langone Medical Center, was co-lead author of the HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. The complete guidelines will be published in the August 2011 issue of the HeartRhythm Journal and Europace.
The new overarching recommendations about cardiac genetic testing include:
The goal of the authors was to evaluate the role of genetic testing and ensure that all physicians have the latest knowledge about the potentially life-saving screening for patients with cardiac conditions that may predispose them to sudden cardiac death and other genetic heart diseases.
The recommendations focus on genetic testing for 13 inherited cardiac conditions including: Long QT Syndrome, Catecholaminergic Polymorphic Ventricular Tachycardia, Brugada Syndrome, Progressive Cardiac Conduction Disease, Short QT Syndrome, Atrial Fibrillation, Hypertrophic Cardiomyopathy, Arrhythmogenic Cardiomyopathy/Arrhythmogenic Right Ventricular Cardiomyopathy, Dilated Cardiomyopathy, Left Ventricular Noncompaction and Restrictive Cardiomyopathy. In addition, the statement includes guidance on the use of genetic testing for out-of-hospital cardiac arrest survivors and post-mortem testing in sudden death cases.
"Genetic testing cannot be viewed as a one-size fits all solution, but should be considered for each disease state," said Dr. Priori, who is also director of Molecular Cardiology and Electrophysiology Laboratories at Fondazione Salvatore Maugeri University in Pavia, Italy. "The recommendations outlined in this document can and should be used as guidance on how each potential disease is evaluated with respect to genetic testing, keeping in mind that each patient is different."
The above story is based on materials provided by NYU Langone Medical Center / New York University School of Medicine. Note: Materials may be edited for content and length.
Cite This Page: